|November 14, 2010|
|12:00 pm - 1:45 pm||Roundtable Discussion #1
Cytotechnology Programs Review Committee: Cytotechnology Education Today - Accreditation Updates and Collaborative Opportunities for Enhancement
Robert A. Goulart, M.D.
1) Understand recent changes to the accreditation process and how to fully comply with CAAHEP Standards and Guidelines, the Curriculum and Entry-Level Competencies; using best practice examples, tools and CPRC-provided guidance (focusing on current challenges faced by programs, institutions, and educators)
2) Understand the relationship of the findings and recommendations of the Educators' Forum Task Forces and the Future of Cytopathology Summit on the Standards/Guidelines, the curriculum, and the overall program review and accreditation process
3) Discuss how legislative and regulatory issues and emerging technologies are affecting the profession, with the further evolution of now needed educational opportunities pertinent to the practice of cytotechnology
4) Outline opportunities for collaboration among communities of interest pertinent to the practice of cytopathology, discussing sponsorship, responsibility for accreditation oversight, and roles of site visitors
The practice and scope of cytotechnology is actively being redefined with education models and curricula currently evolving, a process that will most certainly deepen and accelerate with the final reports of the Task Forces of the 2009 Educators' Forum and the recent Future of Cytopathology Summit. As such, it is imperative for educators to have the appropriate information and tools necessary to ensure that all implemented changes remain compliant with accreditation Standards. As an integral component of this process, the Standards/Guidelines, curriculum and entry-level competencies are currently under review and revision. In this presentation and discussion, the Cytotechnology Programs Review Committee (CPRC) will provide guidance, tools and strategies for adapting to current practice model changes while maintaining compliance. Discussion will further focus on the role of professional organizations in cytotechnology education, challenges faced by existing education programs, and determination of next steps for future collaboration among communities of interest. Best practices of other CAAHEP accredited programs will be offered as examples and serve as points of discussion and debate.
|12:00 pm - 1:45 pm||Roundtable Discussion #2
Guidelines for the Reporting of Non-Gynecological Cytopathology Specimens
Barbara A. Crothers, D.O.
1) Explain why certain data elements in non-gynecological reporting are critical to patient safety
2) Describe the proposed format for non-gynecological reporting of results
3) List 2 elements that have recently been proposed by the College of American Pathologists as additions to non-gynecological reporting
4) Discuss the advantages and disadvantages of report standardization for non-gynecological specimens
Unlike gynecological cytopathology reporting, nongynecological cytopathology reporting has not been widely standardized. In an effort to improve report quality and communication among physicians, the College of American Pathologists Cytopathology Resource Committee recently proposed guidelines for uniform reporting of these specimens, incorporating existing regulations and best practices into the format. This roundtable discussion will introduce the concept of standardized Non-GYN reporting as proposed by the CAP and familiarize pathologists and cytotechnologists with its requirements while allowing for open-forum discussions on the feasibility of implementation, advantages and disadvantages of this effort.
|12:00 pm - 1:45 pm||Roundtable Discussion #3
The New Role of Cytopathology in the Diagnosis and Treatment of Lung Cancer
Maureen F. Zakowski, M.D.
1) Understand the use and limitation of cytology in the diagnosis of lung cancer
2) Be familiar with the immunocytochemical stains necessary to distinguish adenocarcinoma from squamous cell carcinoma
3) Learn what molecular studies are necessary for the complete assessment of adenocarcinoma of the lung
The division of lung cancer into small cell and non-small cell subtypes in pathology is no longer sufficient. The pathologist must work closely with the clinician and understand the necessary sub-typing of lung carcinoma and the molecular studies that will determine treatment. The role of cytology in this setting is vital and participant will learn the tools and techniques needed to maximize the information that may be obtained using cytologic material.
|12:00 pm - 1:45 pm||Roundtable Discussion #4
MOC and Recertification: How Does it Affect Cytopathology? An Update from the American Board of Pathology
Diane Davis Davey, M.D.
1) Define components and requirements for Maintenance of Certification and recertification
2) Explain the role of the American Board of Medical Specialties, and describe why maintenance of certification may be necessary for all practitioners in the future
3) Summarize requirements for Parts 1, 2 and 4 of MOC including self-assessment and practice performance and improvement
4) Describe current plans for the Part 3 modular examination and options to maintain both primary and subspecialty certifications
5) Identify sources of education and information regarding certification including websites and professional societies
Maintenance of certification (MOC) is required for all pathologists certified in 2006. The original certificate is good for 10 years if the pathologist participates successfully in MOC. All 24 member boards of the ABMS now have an MOC program. Individuals certified earlier with lifetime certificates are encouraged to participate in either MOC or voluntary recertification, although the original certificate will not be affected. The voluntary recertification program will end in 2013. MOC has 4 parts: Part 1 is documentation of licensure and practice setting, Part 2 is lifelong learning and self-assessment, Part 3 is a secure examination, and Part 4 includes both peer attestations and practice performance and improvement programs. The Part 3 examination will be modular although the final configuration is still under discussion. Pathologists have the option of maintaining certification in any or all areas in which they obtained a primary certificate.
|12:00 pm - 1:45 pm||Roundtable Discussion #5
Performance Appraisal of Cytotechnologists in an Era of Paradigm Shift
Chiara Sugrue, M.B.A., M.S., SCT(ASCP), CMIAC
1) Identify the role and modalities of a well conducted Performance Appraisal in the current business era
2) Effectively integrate CLIA's requirements in the Cytotechnologist Performance Appraisal
3) Address the integration of QC parameters for the use of semi-automated screening devices into the evaluation
4) Integrate histology and molecular biology correlative parameters for a more objective evaluation
5) Implement ideas for remediation
This roundtable discussion intends to discuss the application of objective methods for the performance appraisal of cytotechnologists in an era of paradigm shift, from screening to diagnosing and interpreting molecular biology test results.
|12:00 pm - 1:45 pm||Roundtable Discussion #6
The Evolving Role of the Cytotechnologist in Non-Gynecologic Cytopathology – The New Age
Beverly Sutkowski, SCT(ASCP)
1) Discuss the changing roles of cytotechnologists in non-gynecologic (NG) exfoliative and fine needle aspiration cytology - in particular, specimen processing, on-site evaluation, and routine screening
2) Discuss the cytotechnologists' skill set valued by pathologists regarding NG cytology
3) Discuss the integration on quality control/quality assurance/quality improvement measures into the cytotechnologists' work flow
4) Discuss cytotechnologists' involvement in ancillary activities
Cytotechnologists today are experiencing new challenges in the way they perform their duties. Traditionally gynecologic cytology has been under close quality control. However, NG cytology standards for the cytotechnologists have not been set. With increasing volumes in NG cytology, cytotechnologists' roles are evolving. Determining the precise roles for the cytotechnologist in NG cytology practice is the challenge facing many cytology laboratories. In this session, we will discuss how we can develop measures to deliver quality services by cytotechnologist in the new age with increasing NG demands.
|12:00 pm - 1:45 pm||Roundtable Discussion #7
The Cell Biology Basis of the Criteria of Malignancy
Andrew H. Fischer, M.D.
1) Review architectural and sub-cellular criteria for diagnosing cancer. A broad range of epithelial, soft tissue, and hematopoietic tumors will illustrate common architectural and sub-cellular criteria of malignancy
2) Review the known Cell Biology basis for the criteria illustrated in Objective 1. Anoikis and alteration in basal-apical polarity will be discussed in relation to architectural criteria. Genetic instability, nuclear lamina organization, nucleoli, and chromatin structure will be described in relation to sub-cellular criteria
3) Practical applications of cell biology to cytology will be discussed
Cytologists and cell biologists are both focused on cancer cells, yet there is very little cross-talk between these two fields. This session aims to create common ground through an in-depth description of the cell biology basis of cytologists’ criteria of malignancy. This session will be useful for cytologists who wish to collaborate or work in cancer research, and for educators who want to stay abreast of the rapid developments in research related to cytology. In addition to facilitating communication and collaboration, it is our experience that an understanding of the cell biology basis for morphologic changes helps reinforce a thorough understanding of the criteria of malignancy. This session therefore should have appeal for cytologists at all levels of experience—from beginners who want to learn or reinforce diagnostic concepts to senior cytologists who want to know the latest developments in the histone code or anoikis mechanisms. The session would also be useful for cell biologists who may wish to learn the diagnostic significance of various cell structural changes. At the end of the session, the audience members will be able to specify at least 6 distinct structural alterations of tumor cells and describe their cell biology basis.
|12:00 pm - 1:45 pm||Roundtable Discussion #8
Cytopathology Innovations as the Cornerstone for Quality Improvement
David Chhieng, M.D., M.B.A., MSHI
1) To understand the role of automation and biomarkers in cervical cytopathology
2) To discuss the practical considerations of innovation adoption and how this impacts laboratory efficiency and quality
3) To describe the implementation of process improvement tools in the cytopathology laboratory and the resulting outcomes in terms of laboratory quality and productivity
The cytopathology laboratory is changing. The challenge of this dynamic environment is to determine how to use current innovations to optimize laboratory efficiency and quality while developing unified workflow solutions. Screening for cervical disease has advanced to include automation as adjunctive methods to traditional cytology. In this session, the moderator will share his views on cytopathology innovations and how the adoption of these new technologies has impacted his laboratory. Furthermore, experiences with workflow modification using process improvement tools will be discussed.